Spermosens AB (STU:9R5) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Spermosens AB Debt-to-Asset?

Spermosens AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.02 Mil. Spermosens AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.00 Mil. Spermosens AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €2.70 Mil. Spermosens AB's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Spermosens AB Debt-to-Asset Historical Data

The historical data trend for Spermosens AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spermosens AB Debt-to-Asset Chart

Spermosens AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.55

0.02

0.14

0.37

0.01

Spermosens AB Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.37	0.39	0.03	0.03	0.01

Competitive Comparison of Spermosens AB's Debt-to-Asset

For the Diagnostics & Research subindustry, Spermosens AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spermosens AB's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Spermosens AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Spermosens AB's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Spermosens AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Spermosens AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.02	+	0)	/	2.699
	=	0.01

Spermosens AB's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.02	+	0)	/	2.699
	=	0.01

Spermosens AB (STU:9R5) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Spermosens AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Spermosens AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Spermosens AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Spermosens AB (STU:9R5) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SPERM:Sweden

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.spermosens.com

Spermosens AB is developing a revolutionary platform technology for diagnosing male-factor infertility and directing to the right infertility treatment. It is a developer of medical device products for male infertility, individualizing In Vitro Fertilization (IVF) diagnostics and treatment creating a new standard for faster and safer IVF treatments.

Spermosens AB Headlines

No Headlines